2022 FSP Summer Conference


Welcome/Overview

Join us at the FSP 2022 Summer Pathology Conference taking place on July 15-17, 2022 at the Breakers in Palm Beach. 

The FSP 2022 Summer Pathology Conference will provide pathologists with education surrounding a wide range of topics and the opportunity to learn and adopt new strategies and tools to aid in the diagnosis and analysis of diseases. The conference will provide practical updates and clinical pearls and pitfalls in the following topics:

GASTROINTESTINAL PATHOLOGY • BREAST PATHOLOGY • CYTOPATHOLOGY

In addition, there will be education on additional topics during interactive read slides and microscopy sessions using an innovative digital platform. New This Year - We are offering a new state mandated course on prevention of medical errors for pathologists on Friday, July 15 from 4:00 pm to 6:00 pm so make plans to join us early!

Registration

hide

Faculty

Syed Z. Ali, MD, FRCPath, FIAC
Professor of Pathology and Radiology
The Johns Hopkins University School of Medicine
Director of Cytopathology
The Johns Hopkins Hospital
Baltimore, MD
Topic: Thyroid Cytology

Sue Boisvert BSN, MHSA, DFASHRM
Senior Patient Safety Risk Manager
The Doctors Company
Jacksonville, FL
Topic: Prevention of Medical Errors for Pathologists

Edi Brogi, MD, PhD
Director of Breast Pathology and Attending Pathologist
Memorial Sloan Kettering Cancer Center
Professor of Clinical Pathology and Laboratory Medicine
Weill Cornell Medical College
New York City, NY
Topic: Breast Pathology

Andre Pinto, MD
Associate Professor of Pathology
Director, Gynecologic Pathology
University of Miami
Miami, FL
Topic: GYN Pathology

 

Rhonda K. Yantiss, MD
Professor of Pathology and Laboratory Medicine
Weill Cornell Medicine
New York, NY
Topic: GI Pathology

 

Agenda

Friday, July 15, 2022

3:00 pm - 6:00 pm
Registration Open  
4:00 pm – 6:00 pm
STATE MANDATED COURSE: Prevention of Medical Errors for Pathologists
Sue Boisvert BSN, MHSA, DFASHRM

Saturday, July 16, 2022

6:30 am - 7:00 pm
Registration Open   
7:00 am - 7:45 am
Sponsored Session   
7:15 am - 8:15 am
Breakfast with Exhibitors   
8:15 am - 8:30 am
Welcome and Introductions
Qihui “Jim” Zhai, MD, FCAP, FSP President
8:30 am - 9:30 am
Fibroepithelial Neoplasms of the Breast
Edi Brogi, MD, PhD
9:30 am - 10:30 am
Breast Pathology: Learning from Mistakes
Edi Brogi, MD, PhD
10:30 am - 11:00 am
Refreshment Break with Exhibitors   
11:00 am - 12:00 pm
Microscopy Session: Unusual Breast Tumors
Edi Brogi, MD, PhD
12:00 pm - 12:15 pm
FSP Business Meeting   
12:30 pm - 1:15 pm
Sponsored Lunch Session   
1:15 pm - 1:45 pm
Dessert Break with Exhibitors   
1:45 pm - 2:45 pm
“Building on the Best” - Thyroid Cytopathology: TBSRTC 2010, 2017 and Beyond
Syed Z. Ali, MD, FRCPath, FIAC
2:45 pm - 3:45 pm
Pancreatic Cytopathology - “Walking On A Tightrope”
Syed Z. Ali, MD, FRCPath, FIAC
3:45 pm - 4:15 pm
Refreshment Break with Exhibitors   
4:15 pm - 5:15 pm
Microscopy Session: Thyroid Cytopathology: Uncovering Diagnostic Pitfalls
Syed Z. Ali, MD, FRCPath, FIAC
5:15 pm - 6:00 pm
Microscopy Read Slides Session: Tubo-Ovarian Carcinoma: The Basics
Andre Pinto, MD
6:00 pm - 7:00 pm
Welcome Reception with Exhibitors   

Sunday, July 17, 2022

7:30 am - 8:30 am
Breakfast with Exhibitors   
8:30 am - 9:30 am
Autoimmune Gastritis, Bacterial Infection, and Chemical Gastropathy: Beyond the ABCs of Gastritis
Rhonda K. Yantiss, MD
9:30 am - 10:30 am
Celiac disease and its mimics: How to avoid a sprue-up when dealing with duodenal biopsies
Rhonda K. Yantiss, MD
10:30 am - 11:00 am
Refreshment Break with Exhibitors   
11:00 am - 12:00 pm
Microscopy Session: Inflammatory Patterns in Small Bowel and Colonic Biopsies: Clues to a Specific Diagnosis
Rhonda K. Yantiss, MD
12:00 pm - 12:15 pm
Closing Remarks
Qihui “Jim” Zhai, MD, FCAP

Venue

The FSP 2022 Summer Pathology Conference will take place at The Breakers.

The Breakers

One South County Road
Palm Beach, FL 33480

The Breakers is SOLD OUT. If you would like to be added to a wait list or would like to book an overflow hotel please contact exec@flpath.org

Accreditation Information

 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Florida Medical Association and the Florida Society of Pathologists. The Florida Medical Association is accredited by the ACCME to provide continuing medical education for physicians.

The Florida Medical Association designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The maximum allocation for participants attending the Prevention of Medical Errors course is 2 AMA PRA Category 1 Credits™.

CRITERIA FOR SUCCESS
Statements of credit/participation will be awarded based on the participant’s attendance at each session and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claim credit form at www.flpath.org/claimcme.  If you have questions about this CME/CE activity, please contact the FSP at 904-309-6261. Credit must be claimed by July 27, 2022.

ACTIVITY FORMAT
Live

TARGET AUDIENCE
This activity is designed to meet the needs of practicing physicians, pathologists, and other specialists involved with pathology.

STATEMENT OF NEED
The field of pathology is constantly changing, and many of the most important advances in the field. In the setting of new technology, techniques and advancements in the field, practice gaps are inevitable. As such, pathologists require ongoing educational opportunities to stay current in order to maintain and improve their knowledge and competence in the field.

COMMERCIAL SUPPORT AND EDUCATIONAL GRANTS: All commercial support and educational grants will be communicated to attendees in advance of the meeting.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, all participants should be able to:

  • Recognize diagnostic features of various lesions.
  • Recognize key features of celiac disease in biopsy samples
  • Identify a differential diagnosis for the malabsorptive pattern of duodenal injury
  • Compare H. pylori-related gastritis from autoimmune gastritis
  • Identify clues to the presence of a medication-related injury to the gastric mucosa
  • Identify idiopathic inflammatory bowel disease and its mimics
  • Describe a differential diagnosis for ischemic patterns of injury
  • Discuss strategies to prevent and mitigate medical errors and create positive patient outcomes.
  • Review The Bethesda System for Reporting Thyroid Cytopathology
  • Discuss the clinical implications of cytopathologic interpretations
  • Recognize common diagnostic pitfalls leading to false positive diagnoses
  • Identify various tumors and pseudo-tumors based on key morphologic characteristics
  • Discuss the importance of a multidisciplinary approach in Pancreatic FNA
  • Identify the cytomorphology of common and uncommon neoplasms
  • Recognize diagnostic features and differential diagnosis in the evaluation of various neoplasms of the breast.
  • Discuss how to prevent diagnostic pitfalls in core needle biopsies and the implications for patient management
  • Discuss the reporting guidelines for benign, borderline, and malignant phyllodes tumors (PTs)

 

PLANNER DISCLOSURES:

Qihui “Jim” Zhai, MD - Has nothing to disclose.

Margaret Neal, MD - Has nothing to disclose.

Carmen Gomez-Fernandez, MD - Has nothing to disclose.

Jesse Kresak, MD - Has nothing to disclose.

Philip Robinson, MD - Has nothing to disclose.

Robert P. Seifert, MD - Has nothing to disclose.

Piotr Borkowski, MD - Has nothing to disclose.

Adrian Palmer, MD - Has nothing to disclose.

Marilyn Bui, MD, PhD- All of the relevant financial relationships listed for this individual have been mitigated.

  • Grant/Research Support:
    • ​John Cleveland, PhD- Principal Investigator
    • Marusyk, PhD, Phillip Altrock, PhD, David Basanta, PhD- Co-Principal Investigator
    • Robert Gilles, PhD, Bethany Niell, MD, PhD- Co- Principal Investigator

​Consultant/Advisor/Contractor:

  • 2019-2022 Scientific Advisory Board Member of ContextVision AB
  • 2020-Present Scientific Advisory Board Member of Aiforia Technologies Oy
  • 2020-2022 Scientific Advisory Board member of Visiopharm
  • 2020-2022 HER2-Low Pathology Advisory Board Member of AstraZeneca
  • Nov 13, 2020 RNA/GEP Scientific Advisory Board member of Foundation Medicine Institute
  • February-April 2021 Group leader of Advances in the Multidisciplinary Care of Patients with Tenosynovial Giant Cell Tumor on a virtual platform by Spire Learning.
  • July 7, 2021 Lete-cel Regional Steering Committee member of GlaxoSmithKline
  • Nov 7, 2021 Caris Life Sciences Advisory panel meeting
  • March, 26,2022 Sarcoma therapy BioAlas Advisory panel meeting

Speaker’s Bureau:

  • Feb 2, 2021 Merck
  • May 14-15 Osler Review Anatomic Pathology virtual slide review (bone and cytopathology)

 

     FACULTY DISCLOSURES

Syed Z. Ali, MD, FRCPath, FIAC - Has nothing to disclose.

Edi Brogi MD PhD - Has nothing to disclose.

Sue Boisvert BSN, MHSA, DFASHRM - Has nothing to disclose.

Andre Pinto, MD - Has nothing to disclose.

Rhonda Yantiss, MD - Has nothing to disclose.

 

 

DISCLOSURE OF THE FLORIDA MEDICAL ASSOCIATION

It is the policy of the Florida Medical Association (FMA) to ensure independence, objectivity and scientific rigor in all approved CME content. CME faculty must present evidence-based data, clarify off-label product use and disclose all relevant financial relationships to the audience. The ideas and opinions expressed during jointly provided events do not necessarily reflect those of the FMA, and the FMA’s approval of course content for AMA PRA Category 1 Credits™. does not constitute an endorsement of the ideas, positions or statements contained therein.  Every effort has been made to ensure that all information provided by the joint provider is accurate and current. However, FMA does not accept responsibility for errors or omissions and accepts no liability for any resulting loss or damage. Attendees agree to participate in this CME activity with full knowledge and awareness that they waive any claim they may have against the FMA for injury or other damage that may result in any way from their participation in this activity.

Sponsors/Exhibitors

Exhibitors at the 2022 FSP Summer Pathology Conference will connect with over 100-150 pathologists and engage in over 12 hours of face-to-face time with attendees.

Other benefits include:

  • Pre and post attendee lists
  • Acknowledgement on the FSP website, meeting signage, and onsite guide
  • Maximize exposure with prize giveaways and breaks scheduled in the exhibit hall
  • 2 complimentary badges to access all exhibit hall activities and all educational sessions

Exhibitor Prospectus

Due to popular demand, the exhibit hall is currently sold out. Sponsorship opportunities still remain, if you are interested in sponsoring, please contact Erin Corrales at exec@flpath.org

Satellite Events

<p>hide</p>

Special Events

<p>hide</p>

Confirmed Exhibitors

Thank you to the following companies for their support of the FSP 2022 Summer Pathology Conference

Agilent/Dako is proud to be a renowned provider of complete pathology solutions, trusted by clinical laboratories around the world in the fight against cancer. Our Dako brand of high-quality diagnostic antibodies, reagents, instruments, software and expertise helps hospitals and research labs around the world deliver accurate results to cancer patients.

 

Aiforia equips pathologists and scientists in preclinical, academic, and clinical labs with the most powerful deep learning artificial intelligence and cloud-based technology to increase the speed, accuracy and consistency of analyzing large and complex medical images across a variety of fields from oncology to neuroscience. Aiforia is composed of an ideal mix of scientists experienced in a variety of medical areas from pathology to cancer diagnostics, software developers who collectively hold over 100 years’ experience in artificial intelligence, and a business team with backgrounds in the pharmaceutical and biotechnology industries.

 

APS Medical Billing is a premier billing firm that provides expert billing and practice management solutions to pathology and laboratory practices nationwide. APS’ clients range in size from a single-physician practice to large, multi-site academic departments, reference and independent labs. The scope of our billing services and proven strategies allow APS to effectively bill for professional, technical and global components of anatomic and clinical pathology services.

Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the U.S. and around the world.

Our ambition is to push the boundaries of science to change the practice of medicine and transform the lives of cancer patients. We target the underlying biology of cancer in Immuno-Oncology, Tumor Drivers/Resistance, DNA Damage Response and Antibody Drug Conjugates. Utilizing precision medicine and biomarker-driven indications we look to dramatically improve five-year survival. Our focus on early disease stages and relapsed patients is to 1) identify and treat patients earlier with curative intent; and 2) support relapsed and refractory patients by tackling primary or acquired resistance.

 

Blueprint Medicines is a global precision therapy company that aims to invent transformative medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we seek to create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy.

 

Caris Life Sciences® is a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. 

 

Cleveland Clinic Laboratories is a full-service, national reference laboratory dedicated to providing world-class care. Our laboratories offer high-quality, clinically impactful pathology and laboratory diagnostics services combined with readily available consultation from experienced pathologists and laboratory scientists.

 

CSI Laboratories is a cancer diagnostics laboratory known for its quality, state-of-the-art laboratory facility, and experienced staff. Our in-house medical team works closely with pathologists, oncologists, and technicians to provide comprehensive global and technical laboratory results throughout the United States. CSI Laboratories offers a full range of comprehensive cancer tests including flow cytometry, cytogenetic analysis, FISH, immunohistochemistry, molecular genetics, and consultations in the areas of hematopathology and surgical pathology.

 

Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for more than 40 years. Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.

 

General Data Healthcare

With over 12 years' experience in laser cassette printing technology, General Data Healthcare is the leader in providing barcode identification and tracking solutions. Our LaserTrack cassette printers consistently produce sharp readable text and barcodes that deliver nearly 100% scan rates, and SlideTrack ESPO delivers automated direct to slide printing and worry-free control slides. Our H&Easyâ„¢ Stain Optimization Service can save you money. See if we can match or improve upon your existing H&E's. Also new: schedule a live interactive demo without leaving your lab, visit us at www.general-data.com/healthcare to schedule your demo!

 

Molecular diagnostic testing for indeterminate thyroid nodules utilizing multi platform testing. ThyGeNEXT is an oncogenic mutation panel that helps identify malignant thyroid nodules and ThyraMIR is a proprietary microRNA gene expression assay that helps to clarify the risk of cancer in thyroid nodules.

 

At Innovative Science Press, we are dedicated to the advancement of pathologists by producing and disseminating educational textbooks. We believe that all pathologists deserve access to quality and affordable medical training in order to help their patients. For this reason, our books are written by some of the most prominent in the field and are reasonably priced. We provide steep discounts to residents and fellows to make our products more affordable and donate frequently to the under-served countries.

 

LabCorp Oncology

Specialty diagnostics at every stage of cancer care. We help you navigate the complex treatment landscape, connecting insights from patients, trials, health systems and managed care partners to power decisions that improve patient outcomes.

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

 

MedReceivables Advisor, LLC is a full service outsourcing medical billing company for the hospital based physician. Our company provides complete accounts receivable management services for hospital-based physicians.

 

At Merck, our goal is to translate breakthrough science into innovative oncology medicines.  As part of our focus on cancer, Merck is committed to clinical research with one of the largest development programs in the industry. 

 

Milestone's innovative products range from specimen collection, to processing, to embedding, and further, including many steps in between. Milestone's mission is to reduce patient anxiety by standardizing and expediting the pre-analytical steps of the histopathology lab and the operating room specimen collection and transportation. In doing so, our goal is to enable superior quality, same-day diagnoses.  Milestone is proud to offer innovative solutions in 6 different fields:  Tissue Processing, Specimen Handling, Frozen sections, Cytology, Macro Digital and Reagents.  

 

MilliporeSigma is a global science and technology company determined to solve the toughest problems in life science. Our tools, services, and digital platforms empower scientists and engineers at every stage, helping to deliver scientific breakthroughs.
We offer cutting-edge technologies, high-quality products, and novel services for diagnostics, research, development, and the manufacturing of biologics and novel therapies. We are dedicated to making research and biotech production simpler, faster, and more successful. Our dedication to the customer experience extends from the lab to our e-commerce platform, which connects scientists in nearly every country with the products, publications, and technical expertise needed to advance their research, manufacturing, and development further and faster.

MSN's Pathology Solutions Team has over 20 years of pathology billing experience working with hospital-based practices and outreach facilities.  We balance the skills and understanding of our expert billing staff with excellent technology,a combination resulting in diligent claims follow-up and collection activity for our pathology clients.  MSN is passionate about client service, and we build strong partnerships with the pathology groups we serve.  We are dedicated to becoming one of the leading pathology billing companies in the country.

 

Our mission and purpose at Myriad Genetics is to advance health and well-being for all, empowering every individual by revealing the answers inside each of us. It is more relevant than ever, and we are committed to fulfilling it – working together to uncover new opportunities, make health more precise and personal, and push the frontiers of what’s possible. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.

 

NeoGenomics is a Florida-based premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. Our vision embodies uncompromising quality, exceptional service, and innovative solutions. We have a network of CAP-accredited, CLIA-certified facilities in the US and offer global capabilities with laboratories in Switzerland and Singapore.

As an industry leader, PathGroup provides comprehensive anatomic, clinical and molecular pathology services. We operate 24 hours a day, 7 days a week to deliver fast and accurate results, with a responsiveness that is unmatched in the industry. PathGroup is privately held and physician centered, designed to work seamlessly with medical practices and provide direct consultation when needed. Our approach is keenly focused on driving better patient outcomes through high-quality, high-service diagnostics from a single point of contact.

 

Proscia is a software company that is accelerating pathology's digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate discovery, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and over 10 of the top 20 pharmaceutical companies rely on Proscia's software each day. 

Quest Diagnostics is the leader in diagnostic information services, including Advanced Diagnostics and related information services, such as molecular and biochemical genetics, cytogenetics, and molecular hematology-oncology. The company’s services combine state-of-the-art technologies in next generation sequencing and nucleic acids, special chemistry and biomarker detection, immunology, flow cytometry, and bioinformatics with interpretative expertise and digital enablement to guide clinical decisions across the continuum of care. The test menu in genetics and genomics includes single gene to whole exome/genome, covering both germline/constitutional and somatic disease conditions. Around the world, elite health systems refer their most challenging cases in hematology-oncology, genetics, and other specialties to Quest Diagnostics for added diagnostic insights. 

Roche Indy is the North American headquarters of the world's largest biotech company, where more than 4,000 people work together to provide insights that help people around the world manage and improve personal health conditions. We lead the industry in the development of diagnostics products for cancer, cardiac health, infectious diseases, women's health and in diabetes management. Diagnostics informs 70 percent of clinical decisions, including the prevention, identification and treatment of diseases, and are a critical part of modern medicine as care becomes more personalized.

 

Seagen is a global biotechnology company that develops and commercializes transformative cancer therapies. We're driven by a singular mission to make a difference for people impacted by cancer.  As an industry leader in antibody drug conjugate (ADC) technology, we pioneered the science of harnessing antibodies designed to deliver cell-killing agents to cancer cells. Three of our four approved medicines are built on this technology. We also focus our research efforts on novel targeted small molecule therapies. In addition, we are leveraging our expertise in empowered antibodies to build a portfolio of proprietary immuno-oncology agents.

 

Our goal is to build awareness around an aggressive and deadly hematologic malignancy called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).  There is a newly approved therapy for BPDCN and we aim to shorten the time to diagnosis so patients can be placed on appropriate therapy in a timely manner.

 

Vachette is a laboratory and pathology consulting firm specializing in revenue cycle auditing, refining revenue cycle processes, and negotiating managed care contracts. We are not a billing company. We utilize a three-tiered process of assessing revenue strategy, revenue management, and revenue insurance to help clients find weaknesses and strengthen process to improve their overall revenue cycle management practices. By specializing and working exclusively with laboratories and pathologists, our team has insight into industry trends and key payer issues that are affecting laboratories today.

 

Veracyte is a pioneering genomic diagnostics company. Our tests provide trustworthy and actionable ANSWERS that improve patient care when diagnostic test results are uncertain. Our tests leverage innovations in genomic technology and machine learning to enable a significantly more confident diagnosis than currently possible in challenging diseases such as thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. We are creating new standards of care in the diagnosis of these diseases by enabling more patients to avoid unnecessary invasive procedures, speeding time to diagnosis and removing costs from the healthcare system.

<p>hide</p>

Coming soon

<p>hide</p>

Networking Events

<p>hide</p>

FAQs

<p>hide</p>

Rare and Interesting Case Competition

<p>hide</p>